12620
51 / Friday, March 16, 2007 / Notices
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 72, No.
estimate of 60,000 caseworkers used for
the burden estimates.
Invitation to participate in on-line survey .........................................................
Estimated Total Annual Burden
Hours: 6,000.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–6974,
Attn: Desk Officer for the
Administration for Children and
Families.
Dated: March 12, 2007.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 07–1231 Filed 3–15–07; 8:45 am]
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Anti-Infective Drugs Advisory
Committee; Notice of Meeting
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Anti-Infective
Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
VerDate Aug<31>2005 15:24 Mar 15, 2007
Respondents: State Title IV–D Agency
Caseworkers.
ANNUAL BURDEN ESTIMATES
Number of re-
Instrument
spondents
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on April 11, 2007, from 8:30 a.m.
to 4 p.m.
Location: Food and Drug
Administration, Center for Drug
Evaluation and Research Advisory
Committee Conference Room, rm. 1066,
5630 Fishers Lane, Rockville, MD.
Contact Person: Lt. Sohail
Mosaddegh, Center for Drug Evaluation
and Research (HFD–21), Food and Drug
Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
sohail.mosaddegh@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512530. Please call the Information
Line for up-to-date information on this
meeting.
Agenda: The meeting will be open to
the public from 8:30 a.m. to 9:30 a.m.,
unless public participation does not last
that long, from 9:30 a.m. to 4 p.m., the
meeting will be closed to permit
discussion and review of trade secret
and/or confidential commercial
information.
FDA intends to make background
material available to the public no later
than 1 business day before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at http://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2007 and scroll down to the
appropriate advisory committee link.
Procedure: On April 11, 2007, from
8:30 a.m. to 9:30 a.m., the meeting is
open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 28, 2007.
Oral presentations from the public will
be scheduled between approximately
Jkt 211001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703
Number of re- Average bur-
Total burden
sponses per den hours per
hours
respondent response
60,000 1 .1 6,000
8:30 a.m. and 9:30 a.m. Those desiring
to make formal oral presentations
should notify the contact person and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on
or before March 21, 2007. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 22, 2007.
Closed Committee Deliberations: On
April 11, 2007, from 9:30 a.m. to 4 p.m.,
the meeting will be closed to permit
discussion and review of trade secret
and/or confidential commercial
information (5 U.S.C. 552b(c)(4)).
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Sohail
Mosaddegh at least 7 days in advance of
the meeting.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: March 8, 2007.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E7–4860 Filed 3–15–07; 8:45 am]
BILLING CODE 4160–01–S
E:\FR\FM\16MRN1.SGM 16MRN1